Omeros CORP 10-Q quarterly reports

Omeros Corporation's Q2 2026 Form 10-Q highlights robust YARTEMLEA sales growth and positive pipeline advancements, alongside a significant repurchase of convertible notes.

Omeros Corporation announces first quarter 2026 financial results, highlighting initial product sales for YARTEMLEA and significant gains from financial instrument revaluation.

Omeros Corporation reports Q3 2025 results, highlighting a significant deal with Novo Nordisk for zaltenibart and an extended PDUFA date for narsoplimab.

Omeros Corporation reported a net loss of $58.9 million for the first six months of 2025, while actively restructuring debt and advancing its clinical pipeline, including a PDUFA extension for narsoplimab.

Omeros Corporation's Q1 2025 results reveal a net loss and going concern uncertainty, despite efforts to restructure debt and advance its clinical programs.

Omeros Corporation's Q3 2024 results reveal ongoing financial challenges and strategic efforts to advance its clinical programs, particularly narsoplimab.

Omeros Corporation announced its second quarter 2024 financial results, highlighted by a new term loan agreement and continued progress in its clinical development programs.

Omeros Corporation reported a net loss of $37.2 million for the first quarter of 2024, with a focus on advancing its clinical-stage drug candidates.